Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are researching regenerative medicine in Japan, one practical question often comes up early: what does the fat collection step actually involve? In adipose-derived stem cell therapy, the cells used for treatment come from your own fat tissue, so the collection procedure is the first physical step of the process. Understanding it in advance can make a consultation more productive and help you plan your time in Osaka.
This article explains, in general terms, how fat collection fits into adipose-derived stem cell therapy at Grand Green Osaka Umekita Clinic in Osaka (Umeda), what questions are worth asking, and what only a physician can determine for you. It is educational information, not medical advice.
The short answer: a small amount of fat, collected as an outpatient
In this treatment, mesenchymal stem cells taken from your own fat tissue are cultured and expanded at a specialized facility, then returned to your body by IV infusion. The clinic describes the amount of fat needed as very small, roughly the size of a few grains of rice. Collection is performed through a small incision under local anesthesia, and it is done on an outpatient basis, so hospitalization is not part of the plan.
That said, how the procedure feels, how long you may need to rest afterward, and whether it is suitable for you are individual matters. Local anesthesia reduces discomfort during the procedure, but it does not mean there is no burden or risk. Your doctor should explain these points before you decide anything.
Why the collection step matters in the overall treatment flow
Stem cell therapy using your own cells is not a single-visit treatment. The cells must first be collected, then cultured for a period of time before they can be administered. This means the fat collection visit and the infusion visit are separated by a culture period. For international patients, this timing is an important planning point, because it affects how many trips or how long a stay may be needed.
Because the treatment is built around your own (autologous) cells, the collected tissue is the starting material for everything that follows. The quality and handling of that material are therefore managed within a controlled process. In Japan, treatments of this kind are provided under a regenerative medicine provision plan, in line with the Act on the Safety of Regenerative Medicine. The details of how a particular clinic manages collection, transport, and culture are worth asking about directly.
What to ask your doctor about fat collection
Before collection, a consultation is the right place to raise practical and medical questions. The following list may help you prepare.
- Is this treatment appropriate for my condition and my overall health, and are there reasons it may not be recommended for me?
- How is the fat collected, and from which area of the body?
- What anesthesia is used, and what discomfort, bruising, or other after-effects can occur?
- What are the possible risks and side effects of both the collection and the later infusion?
- How long is the culture period, and when will the infusion be scheduled?
- What should I tell the clinic about medications, allergies, blood-thinning drugs, or past surgeries?
- What are the total costs, and what is and is not included?
Bringing your medical history, a list of current medications, and any records from your regular doctor can help the physician give you a more accurate explanation.
Why fat, and what the research does and does not show
Mesenchymal stem cells can be found in several tissues, including bone marrow and fat. Fat tissue is considered to contain relatively large numbers of these cells, and collection from fat is generally regarded as less burdensome than bone marrow collection. This is one reason adipose tissue is widely studied as a source of cells for regenerative medicine.
It is important to keep expectations realistic. Mesenchymal stem cells have been reported in research to secrete anti-inflammatory substances and growth factors, and infused cells have been described as tending to move toward sites of inflammation or damage. However, research findings from laboratory studies or individual clinical studies do not guarantee the same results for every patient. The evidence differs by condition, and many questions remain under study. A responsible consultation should discuss what is known, what is uncertain, and how this treatment relates to established standard care. Stem cell therapy should not be understood as a replacement for standard medical treatment.
Planning from overseas: practical points for international patients
If you live outside Japan, the collection step shapes your travel planning. It helps to ask in advance how many visits are involved, how the culture period is handled, and whether follow-up can be coordinated with your home doctor. Clear communication matters in medicine, so it is also worth confirming how language support is provided during the consultation and on the day of the procedure.
Grand Green Osaka Umekita Clinic is located in Umeda, one of Osaka’s main transport hubs, and provides a dedicated information page for international patients as well as multilingual guidance. Using that page to prepare your questions before you book can save time during your visit.
- Gather your medical records and medication list before the consultation.
- Write down your questions about collection, culture, infusion, and follow-up.
- Ask about the expected schedule from collection to infusion before arranging travel.
- Confirm costs and what they include in writing where possible.
Important points about cost, regulation, and decision-making
Adipose-derived stem cell therapy is provided as a self-pay (non-insured) medical service in Japan. This means it is not covered by public health insurance, and costs, risks, side effects, and suitability must be confirmed with a physician at the time of consultation. Prices and conditions can change, so rely on the clinic’s official information and your doctor’s explanation rather than on general articles.
Japan regulates this field through the Act on the Safety of Regenerative Medicine, which requires providers to follow a defined plan and safety management framework. A regulatory framework is not a promise of results, and it does not remove the need for your own careful consideration. Take the time to compare information, ask questions, and avoid making a decision under pressure.
If you are considering adipose-derived stem cell therapy in Osaka, a consultation is the best next step. A doctor can review your situation, explain the fat collection process in detail, and help you decide whether this treatment is a reasonable option or whether other approaches would suit you better.
- 1ConsultationDoctor reviews your situation
- 2Fat collectionSmall amount, local anesthesia
- 3Cell cultureCells expanded at a facility
- 4IV infusionOutpatient administration
This diagram is a conceptual overview of the article content
References
- PubMed: Use of Freshly Isolated Human Adipose Stromal Cells for Clinical Applications. (2017)
- PubMed: The Use of Adipose-Derived Stem Cells for the Treatment of Complex Postoperative Enterocutaneous Fistulas: A Preliminary Case Series Study. (2025)
- PubMed: Adipose tissue for reconstruction and wound healing: applications, challenges, and future directions. (2026)
- PubMed: Cellular therapy with human autologous adipose-derived adult cells of stromal vascular fraction for alopecia areata. (2018)
- PubMed: Platelet-Rich Plasma Versus Microfragmented Adipose Tissue for Knee Osteoarthritis: A Randomized Controlled Trial. (2022)
- PMC: Ultrasound-Assisted Liposuction Does Not Compromise the Regenerative Potential of Adipose-Derived Stem Cells. (2016)
- PMC: Revisiting Fat Graft Harvesting and Processing Technique to Optimize Its Regenerative Potential. (2025)
- PMC: Molecular Characterization of Lipoaspirates Used in Regenerative Head and Neck Surgery. (2019)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.